

## Flupirtine injectable galenic form

### Description

- 5 The present invention relates to a flupirtine-  
containing lyophilisate, to the use of the lyophilisate  
for producing a pharmaceutical composition for  
parenteral administration, to a process for producing a  
10 flupirtine-containing pharmaceutical composition for  
parenteral administration, to a process for producing  
the flupirtine-containing lyophilisate, and to the  
flupirtine-containing pharmaceutical composition  
produced using the lyophilisate.
- 15 Flupirtine (Katadolon®; 2-amino-3-carbethoxyamino-6-(4-  
fluorobenzylamino)pyridine = 2-amino-3-  
ethoxycarbonylamino-6-(p-fluorobenzylamino)pyridine) is  
a centrally acting, non-opiate analgesic. Flupirtine,  
especially in the form of its maleic acid salt, has  
20 been employed successfully for many years for the  
therapy of, for example, neuralgias, pain associated  
with degenerative joint diseases, headaches and  
postoperative pain. According to DE 41 22 166 A1,  
flupirtine can also be employed as agent for  
25 controlling disorders or pathological symptoms which  
are based on muscle tenseness or are a consequence of  
such muscle tenseness. DE 43 27 516 furthermore  
describes the use of flupirtine for treating cerebral  
ischemia and neurodegenerative disorders. DE 195 41 405  
30 A1 discloses the use of flupirtine for the prophylaxis  
and therapy of disorders associated with impairment of  
the haematopoietic cell system. DE 100 48 969 A1  
further describes the use of flupirtine for tinnitus  
treatment. The preparation of flupirtine and  
35 physiologically usable salts thereof is described in DE  
17 95 858 C2, DE 31 33 519 C2 and  
DE 34 16 609 A1.

Flupirtine is mainly administered orally. Thus, DE 93 21 574 U1 describes, for example, pharmaceutical formulations in the form of tablets, granules or pellets which comprise flupirtine maleate as active ingredient. DE 43 19 649 A1 discloses solid flupirtine-containing oral dosage forms with controlled delivery of active ingredient.

However, because of the good analgesic effect of flupirtine, it is desirable to administer flupirtine parenterally in order to achieve a rapid local or systemic effect. The obstacle to this is, however, that flupirtine and physiologically active salts thereof are scarcely soluble in aqueous solutions and in most physiologically tolerated organic solvents.

DE 34 16 609 A1 describes pharmaceutical formulations in the form of injectable flupirtine gluconate solutions which are prepared using suitable solvents. The solvent employed is in particular a mixture of polyethylene glycol and water or a mixture of glycofurool and water. However, the described injection solutions have a number of serious disadvantages. Thus, the flupirtine gluconate solutions prepared using the polyethylene glycol/water or glycofurool/water mixtures are extremely hypertonic and therefore suitable only for intramuscular use. Owing to the relatively low pH of 3.2 to 3.6 and the excipients employed, such as sodium disulphite and propylene glycol, irritation at the administration site is also common. In addition, the described flupirtine gluconate solutions have inadequate physical stability because they are stable only over a very limited period and, after only a few weeks, there is onset of a precipitation process which distinctly limits the shelf life of the finished product. In addition, it has emerged that the physical stability of the flupirtine solutions depends to a large extent also on the storage temperature. Since the

onset of precipitation is distinctly earlier at lower temperatures, it is necessary to maintain a minimum temperature of 20°C during storage of the flupirtine solutions in order to improve the storage stability.

5 Ideally, ampoules containing such solutions for injection ought to be stored at temperatures of 25°C to 30°C, but this is scarcely possible in practice.

10 The technical problem on which the present application is based is therefore to provide means and processes for producing flupirtine-containing pharmaceutical compositions suitable for parenteral administration and not having the disadvantages, known in the state of the art, of parenteral pharmaceutical compositions, that is  
15 to say in particular do not cause side effects such as irritation on administration and, in addition, are physically and chemically stable over a sufficiently long period.

20 The present invention solves the technical problem on which it is based through provision of a lyophilisate which comprises the active ingredient flupirtine in base form or as physiologically tolerated salt and which can be employed to produce a pharmaceutical  
25 composition for parenteral administration.

It has surprisingly been found according to the invention that the disadvantages and problems known in the state of the art to be associated with the handling  
30 and storage of flupirtine solutions for injection can be completely eliminated through the use of the flupirtine lyophilisate according to the invention for producing liquid formulations for parenteral administration. Thus, reconstitution of the flupirtine  
35 lyophilisate according to the invention advantageously leads to very clear flupirtine solutions which are stable for several hours and show no precipitation processes, whereas, with conventional solutions for

injection, flupirtine precipitates immediately after the onset of dissolution. Owing to their stability, the flupirtine solutions produced using the flupirtine lyophilisates according to the invention can therefore  
5 be employed in an excellent manner for parenteral administration, especially as solutions for injection or infusion.

A further surprising advantage of the flupirtine  
10 lyophilisates according to the invention is that purely aqueous media can be employed to produce liquid dosage forms. Whereas only solvent systems which have a high content of organic solvents such as propylene glycol, but not pure aqueous media, can be used to produce  
15 conventional flupirtine solutions for injection, the flupirtine lyophilisates according to the invention are outstandingly soluble in aqueous systems, so that no organic solvents or solubilizing substances need to be employed for dissolving. The flupirtine lyophilisates  
20 according to the invention additionally have the advantage that heating is unnecessary in the dissolving of the lyophilisate, because the flupirtine lyophilisates according to the invention dissolve very rapidly even at room temperature.

25 A further advantage is that the lyophilisates according to the invention can be reconstituted and/or diluted as desired. Thus, the flupirtine lyophilisate according to the invention can be employed equally for producing  
30 solutions for intramuscular or intravenous injection, but also for preparing solutions for infusion. It is also possible in this connection for the reconstituted aqueous preparation to be used as admixture to solutions conventionally used for infusion. This form  
35 of use is advantageous in particular for those patients requiring systemic pain treatment in association with other therapeutic procedures. Since the lyophilisates according to the invention characteristically dissolve

very rapidly, the lyophilisates according to the invention can be reconstituted immediately before use.

In connection with the present invention, a  
5 "lyophilisate" means a material which is obtained by drying in the deep-frozen state under high vacuum through freezing of the solvent, which evaporates in the frozen state. A freeze-dried material obtained in this way is very porous and retains its original  
10 volume. Metabolic functions, enzyme functions and/or biological activity of the material cease after lyophilization.

In connection with the present invention, a  
15 "pharmaceutical composition" or a "medicament" means a mixture which is used for diagnostic, therapeutic and/or prophylactic purposes, that is to say one which promotes or restores the health of a human or animal body, and which includes at least one natural or  
20 synthetically prepared active ingredient which causes the therapeutic effect.

The pharmaceutical composition may include additives normally used in the specialist field, for example  
25 stabilizers, production aids, release agents, emulsifiers, detergents, antioxidants, cake-forming agents or other substances used for producing pharmaceutical compositions, in particular for producing liquid dosage forms.

30 In a preferred embodiment of the invention, the pharmaceutical composition to be produced according to the invention is a liquid pharmaceutical composition for parenteral administration.

35 A "dosage form or pharmaceutical composition for parenteral administration" means a sterile pharmaceutical composition which is administered with

avoidance of the gastrointestinal tract. The advantages of parenteral administration, especially compared with oral administration, are in particular that a very rapid onset of action is possible, that side effects such as, for example, vomiting or gastrointestinal irritation are very substantially avoided, that active ingredients do not undergo gastrointestinal inactivation, that it is also possible to administer active ingredients which are generally inadequately absorbed from the gastrointestinal tract, that the blood level of the administered active ingredient can be calculated beforehand, and that the so-called first pass effect is avoided.

Pharmaceutical compositions for parenteral administration are, in particular, solutions for injection and infusion. "Injections" or "solutions for injection" are preparations with small volumes, in particular between 1 and 20 ml, which are administered as solution, suspension or emulsion. With an "infusion" or "solution for infusion", volumes larger than 100 ml are administered. The commonest parenteral administration routes are intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) administration. Intravenous administration makes it possible for active ingredients which have tissue-irritant effects with other parenteral administration routes to be supplied and administered rapidly. With intramuscular and subcutaneous injections it is necessary to take account of isohydria and isotonicity because, otherwise, local signs of intolerance may appear.

The invention therefore provides for the pharmaceutical composition for parenteral administration which is to be produced using the lyophilisate according to the invention to be a solution for injection or solution for infusion.

The invention provides for flupirtine to be present in the lyophilisates according to the invention possibly either as base or as physiologically tolerated salt,  
5 with, in a preferred embodiment of the invention, the lyophilisate according to the invention comprising at least 100 mg of flupirtine, this stated amount being based on flupirtine base.

10 "Physiologically tolerated salts" of flupirtine mean in particular those flupirtine salts which are in the form of acid addition salts and which have a therapeutic index which is characterized by a sufficiently large distance between the sensitivity curves of the  
15 flupirtine salts for their therapeutic and lethal effect.

Examples of suitable acids for preparing physiologically tolerated flupirtine salts include  
20 hydrohalic acids, sulphuric acid, phosphoric acids, nitric acid, perchloric acid, organic mono-, di- or tricarboxylic acids of the aliphatic, alicyclic, aromatic or heterocyclic series, and sulphonic acids. Preferred examples of suitable acids are formic,  
25 acetic, propionic, succinic, glycolic, lactic, malic, tartaric, citric, ascorbic, maleic, fumaric, hydroxymaleic, pyruvic, phenylacetic, benzoic, p-aminosalicylic, embonic, methanesulphonic, ethanesulphonic, hydroxyethanesulphonic,  
30 ethylenesulphonic, halobenzenesulphonic, toluenesulphonic, naphthalenesulphonic acids, sulphanilic acid and hydrochloric acid. Particularly preferably employed according to the invention for preparing the physiologically tolerated flupirtine salt  
35 is gluconic acid.

In a preferred embodiment of the invention, the physiologically tolerated flupirtine salt is therefore

the formate, acetate, propionate, succinate, glycolate, lactate, malate, tartrate, citrate, maleate, fumarate, pyruvate, phenylacetate, benzoate, embonate, methanesulphonate, ethanesulphonate,  
5 hydroxyethanesulphonate, ethylenesulphonate, halobenzonesulphonate, toluenesulphonate, naphthalenesulphonate, aminobenzenesulphonate or chloride of flupirtine. In a particularly preferred embodiment of the invention, the physiologically  
10 tolerated flupirtine salt is flupirtine gluconate.

The invention further provides for the flupirtine lyophilisate to comprise the acidic constituent of the physiologically tolerated flupirtine salt in an amount  
15 of from 60 mg to 650 mg, preferably from 200 mg to 400 mg, based on 100 mg of flupirtine.

In a preferred embodiment of the invention, the flupirtine lyophilisate according to the invention  
20 additionally comprises at least one cake-forming agent. A "cake-forming agent" or "bulking agent" means an agent which assists the formation of a porous cake with a very large internal surface area during and/or after lyophilization of a material. In a preferred  
25 embodiment, the flupirtine lyophilisate according to the invention comprises mannitol, sucrose or glycine as cake-forming agent. The invention provides in particular for the content of cake-forming agent in the flupirtine lyophilisate according to the invention to  
30 be an amount of from 10 mg to 1000 mg, preferably from 30 mg to 300 mg, based on 100 mg of flupirtine.

A further preferred embodiment of the invention provides for the flupirtine lyophilisate according to  
35 the invention to comprise additionally at least one antioxidant. "Antioxidants" mean excipients able to inhibit, delay or suppress oxidation of a substance, in particular of an active ingredient. Antioxidants may be



free-radical scavengers, easily oxidizable substances or synergists. Free-radical intermediates are often produced in the oxidation of organic compounds. Excipients with sterically hindered phenolic groups can  
5 easily transfer hydrogen radicals to these intermediates, themselves forming more stable molecules. This interrupts the oxidative chain reaction. Free-radical scavengers are employed in particular in non-aqueous, lipophilic systems. By  
10 contrast, easily oxidizable substances are mainly employed in aqueous systems, making use of the fact that every substance to be protected has a particular electrical oxidation potential. The antioxidant to be employed in this case has a distinctly lower oxidation  
15 potential than the substance to be protected. In the presence of oxygen, the antioxidant is then more easily oxidized than the substance to be protected. At the same time, the easily oxidizable excipient acts as proton donor and thus stabilizing. Pharmaceutically  
20 utilizable substances of this type are, in particular, ascorbic acid with a standard oxidation potential of - 0.04 v. Bisulphites and sulphites have a standard oxidation potential of +0.12 v. Synergists comprise a group of excipients which assist the action of  
25 antioxidants either by regeneration of excipient molecules which have already been oxidized, by complexation of traces of heavy metals, by decomposition of peroxides as intermediates of the oxidation or by setting up an oxidation-inhibiting pH.

30 In a preferred embodiment of the invention, the lyophilisate according to the invention comprises sodium bisulphite or ascorbic acid as antioxidant. The invention provides for the antioxidant to be present in  
35 the flupirtine lyophilisate according to the invention in an amount of from 0.5 mg to 10 mg, particularly preferably in an amount of from 2 mg to 5 mg, based on 100 mg of flupirtine.

A further preferred embodiment of the invention provides for the flupirtine lyophilisate according to the invention additionally to comprise at least one  
5 detergent. In connection with the present invention, a "detergent" means an organic surface-active substance which may have an anionic, cationic, ampholytic or nonionic structure. Detergents are also referred to as surfactants. In pharmacy, cationic surfactants are  
10 mainly employed as preservatives or disinfectants. Surfactants may also be employed as w/o or o/w emulsifiers, wetting agents, solubilizers, foam stabilizers or antifoams. The selection of detergents for particular tasks depends both on the chemical  
15 constitution of the hydrophilic and lipophilic groups of the compound employed as detergent, because they determine the affinities for the phases which are present, and on the HLB values, but also on the melting or solidification points and on the viscosities.

20 In a preferred embodiment, the lyophilisate according to the invention comprises a polyvinylpyrrolidone as detergent. Polyvinylpyrrolidones are products of the polymerization of vinylpyrrolidone. A series of  
25 fractions with different molecular sizes or molecular chain lengths is commercially available. A prominent property of polyvinylpyrrolidones is the good solubility both in water and in polar organic solvents such as alcohols, glycols, etc. The invention provides  
30 in particular for the detergent, in particular polyvinylpyrrolidone, to be present in the flupirtine lyophilisate according to the invention in an amount of from 10 mg to 150 mg, particularly preferably in an amount of from 10 mg to 50 mg, based on 100 mg of  
35 flupirtine.

The present invention likewise relates to the use of the flupirtine-containing lyophilisate according to the

invention for producing a pharmaceutical composition for parenteral administration. The invention provides in this connection for the lyophilisate to be used for producing the pharmaceutical composition for parenteral administration by dissolving the lyophilisate in an aqueous medium and/or an organic solvent, resulting in the pharmaceutical composition for parenteral administration. The invention particularly provides for the lyophilisate to be dissolved at room temperature for this purpose. The aqueous medium preferably used according to the invention is water, particularly preferably water for injections. Another embodiment of the invention provides for using a suitable buffer solution as aqueous medium. A further embodiment provides for the lyophilisate to be dissolved in a water/solvent mixture to produce the parenteral pharmaceutical composition.

The present invention likewise relates to a process for producing a flupirtine-containing pharmaceutical composition for parenteral administration, where a flupirtine-containing lyophilisate according to the invention is dissolved in an aqueous medium and/or an organic solvent, and a liquid pharmaceutical composition ready for use is obtained.

The flupirtine lyophilisate according to the invention is preferably dissolved at room temperature. In a particularly preferred embodiment, the flupirtine lyophilisate according to the invention is dissolved in water, in particular water for injections. The flupirtine lyophilisate can, however, also be dissolved in a buffer solution or in a water/solvent mixture.

The isotonicity of the resulting solution can be adjusted via the volume of the aqueous medium used for dissolving. Before administration of the parenteral pharmaceutical composition to be prepared, a decision

can be made as to how the lyophilisate is to be reconstituted and whether dilution can take place where appropriate. Thus, it is equally possible to prepare an intramuscular or intravenous injection from the  
5 lyophilisate according to the invention. The reconstituted aqueous preparation can also be used as admixture to conventional solutions for infusion.

The invention therefore provides for the pharmaceutical  
10 composition for parenteral administration which is produced using the process according to the invention to be a solution for injection. If the solution which is to be produced for injection is to be administered intravenously, the invention provides for the  
15 lyophilisate according to the invention, which preferably contains 100 mg of flupirtine, to be dissolved in from 3 to 20 ml, preferably 9 to 15 ml, of water for injections, buffer solution or water/solvent mixture. If the solution which is to be produced for  
20 injection is to be administered intramuscularly, the invention provides for the lyophilisate according to the invention, which preferably contains 100 mg of flupirtine, to be dissolved in 3 ml of water for injections, buffer solution or water/solvent mixture. A  
25 further preferred embodiment of the invention provides for the pharmaceutical composition for parenteral administration to be a solution for infusion.

The present invention likewise relates to a process for  
30 producing the flupirtine-containing lyophilisate according to the invention, comprising

- a) preparation of a flupirtine solution by adding flupirtine base to an aqueous medium and  
35 dissolving therein, and
- b) freeze drying of the resulting flupirtine solution.

The invention thus provides for flupirtine initially to be dissolved in base form in the first step in an aqueous medium. If the flupirtine lyophilisate to be prepared is to comprise exclusively flupirtine base, the flupirtine base is preferably dissolved in water, in particular water for injections. If the flupirtine lyophilisate to be prepared is to comprise a physiologically tolerated flupirtine salt, the flupirtine base is dissolved in an aqueous solution of the appropriate acid, the acid being selected from the group consisting of gluconic, formic, acetic, propionic, succinic, glycolic, lactic, malic, tartaric, citric, ascorbic, maleic, fumaric, hydroxymaleic, pyruvic, phenylacetic, benzoic, p-aminosalicylic, embonic, methanesulphonic, ethanesulphonic, hydroxyethanesulphonic, ethylenesulphonic, halobenzenesulphonic, toluenesulphonic, naphthalenesulphonic acids, sulphanilic acid and hydrochloric acid. In a preferred embodiment, the lyophilisate to be prepared is to contain flupirtine gluconate. A lyophilisate comprising flupirtine gluconate is therefore prepared by dissolving the flupirtine base in a gluconic acid solution.

In a preferred embodiment of the invention, the aqueous medium, for example water or the acid solution, used to dissolve the flupirtine base is heated to a temperature above room temperature, and kept at this temperature, before addition of the flupirtine base. Only after the heating is flupirtine added to the heated aqueous medium and dissolved therein. In a preferred embodiment, the aqueous medium is heated to a temperature of from 30°C to 90°C, particularly preferably 70°C. The invention further provides for flupirtine to be added with stirring to the preferably heated aqueous medium. The solution is then stirred until flupirtine has completely dissolved.

The invention further provides for the flupirtine solution prepared in this way subsequently to be filtered. A filter with a pore width of 0.2  $\mu$ m is particularly preferably employed in this connection. The preferably filtered flupirtine-containing solution is then introduced into freeze-drying bottles, which are then provided with freeze-drying stoppers. The flupirtine solution is frozen by storing the freeze-drying bottles at -45°C.

The invention provides for the actual freeze drying to comprise a main drying and an after-drying. In a preferred embodiment, the main drying takes place at a temperature of from -37°C to -23°C under a pressure of from 10 to 100 mbar. In a preferred embodiment, the subsequent after-drying takes place at a temperature of 27°C under a pressure of 0.0001 mbar. After the freeze drying, the freeze dryer is destressed with N<sub>2</sub>. Sterile closure of the bottles containing the flupirtine lyophilisate then preferably takes place under a nitrogen atmosphere.

The present invention likewise relates to the liquid pharmaceutical composition for parenteral administration which is obtainable through the flupirtine lyophilisate according to the invention.

The present invention is explained in more detail by the following examples.

#### Example 1: Production of a flupirtine-containing lyophilisate

7.81 g of gluconic acid d-lactone are dissolved in 70 ml of water and then heated to 70°C. while stirring at this temperature, 3.33 g of flupirtine are added and stirred until completely dissolved. The mixture

obtained in this way is filtered through a filter with a pore width of 0.2  $\mu$ m. After the filtration, the solution is dispensed into freeze-dried bottles and provided with suitable freeze-drying stoppers. The contents are frozen by storing the bottles at -45°C. The main drying of the freeze-drying process takes place at -37°C to -23°C under 100 to 10 mbar. The after-drying is then carried out at 27°C under 0.0001 mbar. After the drying, the freeze dryer is destressed with N<sub>2</sub>. The bottles are then closed under a nitrogen atmosphere.

#### Example 2: Production of a flupirtine-containing lyophilisate

7.81 g of gluconic acid d-lactone are dissolved in 70 ml of water and then heated to 70°C. while stirring at this temperature, 4.0 g of mannitol and 3.33 g of flupirtine are added and stirred until the added compounds have completely dissolved. The mixture obtained in this way is filtered through a filter with a pore width of 0.2  $\mu$ m. After the filtration, the solution is dispensed into freeze-drying bottles and provided with suitable freeze-drying stoppers. The contents are frozen by storing the bottles at -45°C. The main drying of the freeze-drying process takes place at -37°C to -23°C under 100 to 10 mbar. The after-drying is then carried out at 27°C under 0.0001 mbar. After the drying, the freeze dryer is destressed with N<sub>2</sub>. The bottles are then closed under a nitrogen atmosphere.

#### Example 3: Production of a flupirtine-containing lyophilisate

7.81 g of gluconic acid d-lactone are dissolved in 70 ml of water and then heated to 70°C. while stirring at this temperature, 7.5 g of sucrose, 0.4 g of

polyvinylpyrrolidone (MW approximately 11 500;  
collidone PF17; BASF) and 3.33 g of flupirtine are  
added. The solution is stirred until the added  
substances have completely dissolved. The mixture  
5 obtained in this way is filtered through a filter with  
a pore width of 0.2  $\mu$ m. After the filtration, the  
solution is dispensed into freeze-drying bottles and  
provided with suitable freeze-drying stoppers. The  
contents are frozen by storing the bottles at -45°C.  
10 The main drying of the freeze-drying process takes  
place at -37°C to -23°C under 100 to 10 mbar. The  
after-drying is then carried out at 27°C under 0.0001  
mbar. After the drying, the freeze dryer is destressed  
with N<sub>2</sub>. The bottles are then closed under a nitrogen  
15 atmosphere.

#### Example 4: Composition of a flupirtine lyophilisate

One bottle contains:

20           100.00 mg of flupirtine  
          257.85 mg of gluconic acid  
          300.00 mg of mannitol.

#### 25   Example 5: Composition of a flupirtine lyophilisate

One bottle contains:

          100.00 mg of flupirtine  
30       257.85 mg of gluconic acid  
          225.00 mg of sucrose  
          12.00 mg of polyvinylpyrrolidone  
                  (Kollidon 17 PF, BASF).

#### 35   Example 6: Composition of a flupirtine lyophilisate

One bottle contains:



100.00 mg of flupirtine  
257.85 mg of gluconic acid  
120.00 mg of mannitol  
4.50 mg of sodium bisulphite

5

#### Example 7: Composition of a flupirtine lyophilisate

One bottle contains:

10        100.00 mg of flupirtine  
          257.85 mg of gluconic acid  
          207.00 mg of mannitol

#### 15        Example 8: Production of a liquid pharmaceutical composition

3 ml of water for injections is added to a bottle of the lyophilisate described in Example 7. After occasional swirling, a clear solution is obtained after  
20        about 1 min. The solution is distinctly hypertonic at 980 mosmol/kg.

#### Example 9: Production of a liquid pharmaceutical composition

25

9 ml of water for injections is added to a bottle of the lyophilisate from Example 7. while swirling occasionally, a clear solution is obtained after about  
1 min. The solution is virtually isotonic at 305  
30        mosmol/kg.

